Moreover, anti-PD-1 and anti-PD-L1 antibody monotherapy is not beneficial in terms of PFS or overall survival (OS) in patients with EGFR mutation- or ALK fusion-positive NSCLC [8–10]. Here, ALK is linked to non-small cell lung carcinoma.